GHRP-2
A growth hormone–releasing peptide studied in earlier clinical research; not FDA-approved.
What it is
GHRP-2 is one of the original growth-hormone-releasing peptides, studied in the 1990s and 2000s as both a research tool and a potential diagnostic agent. It stimulates GH release and, notably, appetite — it acts on the ghrelin receptor.
It was never developed into an approved US drug. The human research that exists is early-phase and mostly diagnostic in nature; the bodybuilding uses marketed online were never the subject of controlled trials.
What researchers have actually studied it for
Growth-hormone release and GH-deficiency diagnostics in early clinical research; appetite stimulation via the ghrelin receptor.
How it works
A six-amino-acid ghrelin-receptor agonist: it mimics the stomach's hunger hormone at the pituitary (releasing GH) and at appetite circuits (stimulating hunger). Its GH release is robust but blunter than natural pulsing, with mild cortisol and prolactin spillover in early studies.
The molecule itself
A synthetic hexapeptide with unnatural amino acids (D-alanine, naphthylalanine) — designed potency in a small package, predating knowledge of its own receptor. Robust GH release with moderate appetite, cortisol and prolactin effects; short half-life.
Where it came from
Born in the pre-ghrelin era — GHRPs were discovered before the receptor they activate was identified in 1996, a rare case of drug before target. GHRP-2 found a modest legitimate niche as a GH-deficiency diagnostic in Japan while its therapeutic development quietly ended.
The timeline
1980s–90s
Developed in the pre-ghrelin secretagogue program.
1996
The ghrelin receptor's identification retroactively explains the family.
2000s
Diagnostic use for GH deficiency established in Japan; therapeutic development ends.
What the research record actually contains
- Early clinical pharmacology of GH release and appetite stimulation.
- Diagnostic-use literature for GH deficiency, including regulatory acceptance in Japan.
- No controlled trials on body composition or performance in healthy adults.
What could change this assessment
A closed scientific file with a historical footnote: the family's role in discovering the ghrelin system was genuine science. Nothing current is studying it for the uses it's sold for.
What's known about risks
Acute studies reported tolerability; appetite increase, cortisol/prolactin nudges and water retention recur in the literature. Chronic wellness-pattern use has never been safety-characterized.
Where it stands legally
Not an approved US therapeutic; gray-market channel; prohibited in tested sport.
Worth asking a licensed provider
- 1.Is stimulating appetite compatible with my goals at all?
- 2.Why this vintage compound over anything with an active development program?
- 3.What testing implications exist if I compete?
Common claims, corrected
“GHRP-2 is approved in Asia, so it's a real drug.”
Reality: It saw diagnostic (testing) use in Japan — a niche legitimacy that says nothing about therapeutic wellness use anywhere.
“Appetite stimulation means it 'boosts metabolism.'”
Reality: It activates the hunger hormone's receptor — appetite is the direct effect, and no metabolic outcome trial exists.
GHRP-2 FAQ
Does GHRP-2 increase appetite?
Yes — it activates the ghrelin ('hunger hormone') receptor, and increased appetite is one of its most consistently observed effects. Whether that's a feature or a problem depends entirely on the goal.
Is GHRP-2 approved anywhere?
It has seen diagnostic use in some countries but is not an FDA-approved therapeutic in the United States.
GHRP-2 vs ipamorelin — what's the difference?
Both hit the ghrelin receptor, but ipamorelin is more selective — less appetite stimulation and less effect on cortisol and prolactin in early studies. Neither has controlled-trial evidence for body-composition outcomes.
What's GHRP-2's place in history?
The GHRPs were drugs before their target was known — their existence helped force the ghrelin receptor's 1996 discovery, a rare backwards chapter in pharmacology.
GHRP-2 vs GHRP-6?
Siblings separated by appetite: GHRP-6's hunger effect is stronger; GHRP-2 trades some of it for potency. Both share the family's absent outcome evidence.